View More Recent Stories

Aug 5, 2015 07:30AM Arrowhead to Present at Jefferies 2015 Hepatitis B Summit
Aug 4, 2015 04:01PM Arrowhead Reports Fiscal 2015 Third Quarter Financial Results
Jul 28, 2015 04:30PM Arrowhead to Report Fiscal 2015 Third Quarter Financial Results
Jul 8, 2015 07:30AM Arrowhead Receives Regulatory Clearance for ARC-AAT Phase 1 in the United Kingdom and New Zealand
Jul 2, 2015 07:30AM Arrowhead Initiates Dosing of ARC-AAT in Patients with Alpha-1 Antitrypsin Deficiency
Jun 17, 2015 07:30AM Arrowhead Receives Regulatory Clearance to Begin Additional Phase 2b Studies of Hepatitis B Candidate ARC-520
Jun 10, 2015 12:27PM Arrowhead Receives Orphan Drug Designation for ARC-AAT
May 27, 2015 07:30AM Arrowhead to Present at Jefferies 2015 Healthcare Conference
May 11, 2015 04:01PM Arrowhead Reports Fiscal 2015 Second Quarter Financial Results
May 6, 2015 03:15PM Arrowhead Presents Data on Potential RNAi Candidate Targeting Factor 12 Mediated Angioedemic and Thromboembolic Diseases
May 5, 2015 07:30AM Arrowhead Completes Dosing Healthy Volunteers and Initiates Transition to Patients in Phase 1 Study of ARC-AAT
May 4, 2015 04:01PM Arrowhead to Report Fiscal 2015 Second Quarter Financial Results
Apr 30, 2015 07:30AM Arrowhead Publishes Data on Advances in Subcutaneous siRNA Delivery
Apr 28, 2015 04:01PM Arrowhead to Present at Upcoming Conferences
Apr 13, 2015 07:30AM Arrowhead Cleared to Proceed with Multiple Dose Phase 2b Study of ARC-520
Mar 5, 2015 07:30AM Arrowhead Acquires Novartis’ RNAi Research and Development Portfolio
View More Recent Stories